What is Tevogen Bio?
Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified T cell therapeutics. The company's core mission is to harness the power of the human immune system by isolating, expanding, and banking virus-specific T cells from healthy donors. This proprietary platform enables the creation of readily available therapeutic products, aiming to provide rapid access to potentially life-saving immunotherapies for patients with compromised immune systems, including transplant recipients, cancer patients undergoing chemotherapy, and individuals with severe viral infections. Tevogen's approach addresses unmet medical needs in areas where conventional treatments have limited effectiveness, particularly for patients suffering from opportunistic infections and immune-related complications.
How much funding has Tevogen Bio raised?
Tevogen Bio has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2024): $50M, investors not publicly disclosed
What's next for Tevogen Bio?
With this significant strategic investment, Tevogen Bio is poised to accelerate its clinical development pipeline and scale its proprietary platform technology. The company's focus on allogeneic cellular therapies, which can be manufactured at scale and stored for immediate deployment, positions it to address the urgent need for accessible immunotherapies. Future efforts will likely concentrate on advancing its T cell therapeutic candidates through further clinical trials to validate their safety and efficacy across various disease indications, thereby solidifying its standing in the competitive landscape of next-generation immunotherapy innovation.
See full Tevogen Bio company page
